Chao-Chi Ho1, Wei-Yu Liao1, Chih-An Lin2, Jin-Yuan Shih1, Chong-Jen Yu1, James Chih-Hsin Yang3. 1. Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Republic of China. 2. Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Republic of China. 3. Department of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Republic of China; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Republic of China. Electronic address: chihyang@ntu.edu.tw.
Abstract
INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used. Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment. METHODS: Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib. Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry. EGFR, AKT, MEK, and ERK phosphorylation were determined. An anchorage-dependent colony formation assay was used for drug sensitivity. RESULTS: An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib. Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib. CONCLUSIONS: A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway. Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.
INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used. Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment. METHODS: Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib. Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry. EGFR, AKT, MEK, and ERK phosphorylation were determined. An anchorage-dependent colony formation assay was used for drug sensitivity. RESULTS: An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib. Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib. CONCLUSIONS: A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway. Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.
Authors: Bruno Bockorny; Maria Rusan; Wankun Chen; Rachel G Liao; Yvonne Li; Federica Piccioni; Jun Wang; Li Tan; Aaron R Thorner; Tianxia Li; Yanxi Zhang; Changhong Miao; Therese Ovesen; Geoffrey I Shapiro; David J Kwiatkowski; Nathanael S Gray; Matthew Meyerson; Peter S Hammerman; Adam J Bass Journal: Mol Cancer Ther Date: 2018-04-13 Impact factor: 6.261
Authors: Morana Vojnic; Daisuke Kubota; Christopher Kurzatkowski; Michael Offin; Ken Suzawa; Ryma Benayed; Adam J Schoenfeld; Andrew J Plodkowski; John T Poirier; Charles M Rudin; Mark G Kris; Neal X Rosen; Helena A Yu; Gregory J Riely; Maria E Arcila; Romel Somwar; Marc Ladanyi Journal: J Thorac Oncol Date: 2019-03-01 Impact factor: 15.609
Authors: Hiroki Sato; Adam J Schoenfeld; Evan Siau; Yue Christine Lu; Huichun Tai; Ken Suzawa; Daisuke Kubota; Allan J W Lui; Besnik Qeriqi; Marissa Mattar; Michael Offin; Masakiyo Sakaguchi; Shinichi Toyooka; Alexander Drilon; Neal X Rosen; Mark G Kris; David Solit; Elisa De Stanchina; Monika A Davare; Gregory J Riely; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2020-03-02 Impact factor: 12.531
Authors: Trever G Bivona; Collin M Blakely; Julia K Rotow; Philippe Gui; Wei Wu; Victoria M Raymond; Richard B Lanman; Frederic J Kaye; Nir Peled; Ferran Fece de la Cruz; Brandon Nadres; Ryan B Corcoran; Iwei Yeh; Boris C Bastian; Petr Starostik; Kimberly Newsom; Victor R Olivas; Alexander M Wolff; James S Fraser; Eric A Collisson; Caroline E McCoach; D Ross Camidge; Jose Pacheco; Lyudmila Bazhenova; Tianhong Li Journal: Clin Cancer Res Date: 2019-09-23 Impact factor: 12.531